About Us
Cell to Cure is a clinical-stage biopharmaceutical company developing cell-based therapies.
Making Stem Cells
Available for Therapy
As a promising new therapeutic concept, pre-clinical studies and clinical trials suggest that stem cells can be used in the treatment of multiple disease conditions with involvement of inflammation and immunological activity, blood circulatory disturbance, fibrosis and scar development.
Our goal is to make these mesenchymal stromal cells available for therapies as a treatment option for patients with unmet needs.
Based on years of
development
Cell to Cure is a spinout from the Cardiology Stem Cell Centre at Rigshospitalet, Copenhagen University Hospital, Denmark. We have a proprietary manufacturing process to produce off-the-shelf cell products based on many years of development.
Our cell products are designed to be readily available and used across a broad range of diseases characterised by inflammation, immune dysregulation, impaired blood circulation, fibrosis, and tissue scarring.
Ownership and Organisation
Cell to Cure ApS is a Danish established and privately held company. The majority owner is Endeavour Cells ApS, owned by entrepreneur Anders Østergaard who also functions as Chairman of the Board in Cell to Cure.
Meet our
Management Team
Get in touch
Proven Safety in
Clinical Trials
The cell products have proven safety in more than 300 patients in several phase I and II clinical trials for treatment of conditions such as autism and leaky gut syndrome in children, non-ischemic heart failure, diabetic foot ulcer, complications following lung transplantation, reduced tear production in Sjögren’s syndrome, and radiation-induced dry mouth in head and neck cancer patients.
